The Urgent Need for Cancer Screening in South Africa

By Crystal Lubbe

February 11, 2025

Cancer screening

In South Africa, more women are dying from breast and cervical cancers than from HIV. This alarming statistic highlights the urgent need for improved cancer screening in South Africa and early detection measures, especially in rural and underserved areas. The article discusses the obstacles within the healthcare system, such as long travel distances, inadequate infrastructure, and funding challenges that hinder effective cancer care.

Key Insights into Cancer in South Africa

– Cancer Mortality: Breast and cervical cancers claim more lives among women in South Africa than HIV, emphasising the critical need for enhanced cancer care and prevention strategies.
– Screening and Early Detection: Early detection is essential for effective cancer treatment. However, South Africa grapples with significant challenges, such as long travel distances and inadequate facilities, which often lead to late-stage diagnoses.
– Funding and Support: NGOs like PinkDrive play a vital role in cancer awareness and screening, relying heavily on external funding due to a lack of support from the Department of Health.
– Lifestyle Factors: Making lifestyle changes—quitting smoking, reducing alcohol consumption, eating a balanced diet, and staying active—can significantly lower cancer risks.
– Advanced Treatments: South Africa is at the forefront of targeted alpha therapies and nuclear medicine for cancer treatment, but access is often limited due to funding and infrastructure constraints.

Cancer Burden in South Africa

The country faces a high cancer incidence, with breast and cervical cancers among the top causes of cancer-related deaths. In 2020, cervical cancer was the leading cause of cancer mortality among women, despite a higher incidence of breast cancer. The South African healthcare system faces numerous challenges, including underfunding, inadequate infrastructure, and long distances to healthcare facilities. These issues contribute to late-stage diagnoses and reduced survival rates for breast and cervical cancers. Cervical cancer is preventable through HPV vaccination and regular screening. Yet, many still lack access to these crucial preventive measures, particularly in low- and middle-income countries. Worldwide, breast cancer is the leading cause of cancer deaths among women. In South Africa, breast cancer mortality rates have increased significantly over the years.

Health Economic and Policy Challenges

The high mortality rates from breast and cervical cancers have significant economic consequences, including increased healthcare costs and lost productivity. Investing in preventive measures such as vaccination and cancer screening in South Africa could mitigate these costs over time. Enhancing access to early detection and treatment can significantly improve survival rates. However, addressing systemic issues like funding and infrastructure is crucial, particularly in rural and underserved areas.

There is a pressing need for policy reforms and increased funding to support NGOs and public health initiatives aimed at cancer prevention and early detection. Integrating these services into the National Health Insurance (NHI) framework is essential for ensuring equitable healthcare access. Public health initiatives should focus on promoting lifestyle changes and raising awareness about cancer risks. Additionally, leveraging advanced treatments like nuclear medicine can improve outcomes, which requires better funding and infrastructure support.

In conclusion, enhanced cancer screening in South Africa and investment in early detection are paramount for improving health outcomes and reducing mortality rates.

Reference url

Recent Posts

KEYTRUDA combination therapy
KEYTRUDA Combination Therapy Gains FDA Approval for Advanced Triple-Negative Breast Cancer

By João L. Carapinha

June 26, 2026

The FDA has approved KEYTRUDA combination therapy with Trodelvy as first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 at a Combined Positive Score of 10 or greater. This marks the first regulatory nod for a PD-...
Trodelvy ADC approval
Advancements in Breast Cancer Treatment Following Trodelvy ADC Approval

By João L. Carapinha

June 25, 2026

The Trodelvy ADC approval by the European Commission delivers the first antibody-drug conjugate approved for first-line use in adults with unresectable or metastatic triple-negative breast cancer who are ineligible for PD-1 or PD-L1 inhibitors. This
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...